Stockscreener 앱 받기
13.99
0.29%
-0.04
시장 영업 전:
14.00
0.010
+0.07%
전일 마감가:
$14.03
열려 있는:
$13.96
하루 거래량:
874.73K
Relative Volume:
0.78
시가총액:
$11.68B
수익:
$3.85B
순이익/손실:
$667.93M
주가수익비율:
21.29
EPS:
0.657
순현금흐름:
$142.30M
1주 성능:
-1.48%
1개월 성능:
-1.89%
6개월 성능:
+12.55%
1년 성능:
-11.17%
1일 변동 폭
$13.95
$14.07
1주일 범위
$13.95
$14.23
52주 변동 폭
$12.26
$16.17
Dr Reddys Laboratories Ltd Adr Stock (RDY) Company Profile
명칭
Dr Reddys Laboratories Ltd Adr
전화
-
주소
-
RDY을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RDY
Dr Reddys Laboratories Ltd Adr
|
13.99 | 11.68B | 3.85B | 667.93M | 142.30M | 0.657 |
|
ZTS
Zoetis Inc
|
143.49 | 63.27B | 9.39B | 2.62B | 2.22B | 5.8121 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.31 | 45.67B | 29.96B | 957.25M | 4.77B | 0.2956 |
|
HLN
Haleon Plc Adr
|
9.04 | 39.27B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
20.21 | 23.02B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
448.93 | 20.66B | 3.08B | 1.24B | 1.07B | 25.61 |
Dr Reddys Laboratories Ltd Adr Stock (RDY) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-05 | 업그레이드 | HSBC Securities | Hold → Buy |
| 2024-12-19 | 다운그레이드 | Nomura | Buy → Neutral |
| 2024-01-11 | 다운그레이드 | Jefferies | Buy → Underperform |
| 2023-08-29 | 다운그레이드 | HSBC Securities | Buy → Hold |
| 2023-05-18 | 다운그레이드 | Bernstein | Outperform → Mkt Perform |
| 2023-03-17 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2023-01-30 | 개시 | JP Morgan | Underweight |
| 2022-11-14 | 다운그레이드 | Credit Suisse | Neutral → Underperform |
| 2022-01-03 | 재개 | BofA Securities | Neutral |
| 2021-07-27 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2021-02-02 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2020-09-18 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2020-09-18 | 업그레이드 | Investec | Sell → Hold |
| 2020-01-28 | 다운그레이드 | CLSA | Buy → Outperform |
| 2020-01-27 | 다운그레이드 | CLSA | Buy → Outperform |
| 2020-01-09 | 업그레이드 | Citigroup | Sell → Buy |
| 2019-11-04 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2019-09-04 | 업그레이드 | Credit Suisse | Underperform → Outperform |
| 2019-07-01 | 업그레이드 | Macquarie | Neutral → Outperform |
| 2019-06-20 | 개시 | Deutsche Bank | Hold |
| 2019-06-11 | 개시 | Barclays | Equal Weight |
| 2019-05-20 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2019-02-19 | 업그레이드 | CLSA | Outperform → Buy |
| 2019-01-17 | 다운그레이드 | Citigroup | Neutral → Sell |
| 2017-09-21 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2017-08-31 | 업그레이드 | CLSA | Underperform → Outperform |
| 2017-07-28 | 다운그레이드 | CLSA | Underperform → Sell |
| 2016-07-27 | 다운그레이드 | HSBC Securities | Hold → Reduce |
| 2016-07-27 | 다운그레이드 | Jefferies | Hold → Underperform |
| 2016-02-10 | 업그레이드 | Credit Agricole | Underperform → Buy |
| 2015-11-10 | 다운그레이드 | Citigroup | Buy → Neutral |
모두보기
Dr Reddys Laboratories Ltd Adr 주식(RDY)의 최신 뉴스
Truist Financial Corp Sells 21,444 Shares of Haleon PLC Sponsored ADR $HLN - Defense World
Esperion Reaches Settlement Agreement with ANDA Filer, Dr. Reddy’s Laboratories, Not to Market Generic Versions of NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) Prior to April 19, 2040 - GlobeNewswire Inc.
Asian ADRs Rise As Regional Firms Show Mixed Performance - Finimize
LLY Stock Quote Price and Forecast - CNN
Dr Reddys Share Price Update: Company Reports Negative Monthly Returns - Meyka
GDR, ADR & IDR Companies Stock Prices | IIFL Capital - India Infoline
NVO Stock Quote Price and Forecast - CNN
Asian ADRs In The US Start The Week On A High Note - Finimize
Bizarre Stock Volatility? How Is H1B News Affecting Infosys & Wipro Share Prices On Saturday? - Free Press Journal
Asian ADR Index Edges Up As LG Display Leads - Finimize
Dr. Reddy’s Laboratories Allots Equity Shares Under Employee Stock Option Scheme - The Globe and Mail
Dr Reddy's shares fall as USFDA flags Hyderabad plant with 5 observations - Business Standard
Asian ADRs Gain As Investors Show Renewed Interest - Finimize
Asian Equities In The US Logged Broad Gains This Session - Finimize
Mixed Performance For Asian Stocks Traded In The US - Finimize
Dr. Reddy’s Laboratories Allots Equity Shares to Employees - TipRanks
Invesco Ltd. Has $8.12 Million Stake in ATRenew Inc. Sponsored ADR $RERE - Defense World
Validea's Top Health Care Stocks Based On Peter Lynch8/25/2025 - Nasdaq
Coya Therapeutics Announces FDA Acceptance of Investigational New Drug (IND) Application for COYA 302 for the Treatment of Amyotrophic Lateral Sclerosis (ALS) - Barchart.com
National Bank of Canada FI Boosts Stock Position in Dr. Reddy's Laboratories Ltd $RDY - MarketBeat
Asian ADRs Trade Lower As S&P Asia 50 Index Drops - Finimize
Asian Tech Names Lift US-Traded Stocks To A Small Gain - Finimize
Dr. Reddy’s Subsidiary Imperial Dissolved Following NCLT Approval - TipRanks
(PDF) ADRs and underlying stock returns: empirical evidence from India - researchgate.net
Trump Tariff Impact: Infosys, Wipro, HDFC Bank, Other ADR Shares Drop After US Levies 50% Tariff On India - MSN
Asian Stocks In The US See Mixed Moves Across Sectors - Finimize
Trump hikes tariffs on India by additional 25% citing Russian oil trade; iShares India ETF, ADRs react - Moneycontrol
Asian ADRs Fall As Winners And Losers Stand Out - Finimize
Dr Reddys Laboratories Faces Continued Stock Decline Amid Broader Market Challenges - Markets Mojo
Asian ADRs Falter On US Markets As Fintechs Slide - Finimize
Trump’s Tariffs on India highlights: Sensex falls 800 points, Trump launches fresh attack on India for Russia ties - Mint
Trump Tariff Impact: Infosys, Wipro, HDFC Bank, Other ADR Shares Drop After US Levies 25% Tariff On India - MSN
Dr Reddys Laboratories Ltd Adr (RDY) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.68%
0.35%
자본화:
|
볼륨(24시간):